Last reviewed · How we verify

NCT04836481

A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury

Completed Last updated 29 February 2024
What this trial tests

trial testing Serum Sample Collection in Traumatic Brain Injury in 10 participants. Completed in 1 October 2023.

Timeline
1 January 2021
Primary endpoint
1 May 2022
1 October 2023

Quick facts

Lead sponsorUniversity of Cincinnati
StatusCompleted
Study typeOBSERVATIONAL
Enrollment10
Start date1 January 2021
Primary completion1 May 2022
Estimated completion1 October 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Cincinnati

Who can join

Adults 18 to 75, any sex, with Traumatic Brain Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims is to describe the pharmacokinetic properties of levetiracetam through measurement of serum concentrations in critically ill, severe traumatic brain injury patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Traumatic Brain Injury

Currently open trials in the same condition.

Other University of Cincinnati trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04836481.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing